Clinical Trials Logo

Stomach Cancer, Adenocarcinoma clinical trials

View clinical trials related to Stomach Cancer, Adenocarcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT05620628 Recruiting - Clinical trials for Stomach Cancer, Adenocarcinoma

Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)

Start date: January 5, 2023
Phase: Phase 2
Study type: Interventional

For patients who failed primary chemotherapy with MET amplification, The efficacy and safety of the chemotherapy are evaluated by using dervalumab and saboritinib in combination.

NCT ID: NCT03995017 Active, not recruiting - Clinical trials for Esophagus Cancer, Adenocarcinoma

Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma

RiME
Start date: January 9, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The study population is advanced gastric, gastroesophageal, and esophageal adenocarcinoma participants who have failed upfront standard of care chemotherapy. The goal is to demonstrate that Rucaparib plus Ramucirumab with or without Nivolumab has a higher response rate than what has been reported for Ramucirumab in previously treated patients. Trial will be a phase 1/2 trial. The Phase 1 portion will determine the recommended Phase 2 treatment dose for the combination of Rucaparib plus Ramucirumab and Nivolumab and enroll approximately 6-9 participants. The Phase 2 portion of the study will involve 52 participants allocated between two treatment groups comparing Rucaparib plus Ramucirumab with or without Nivolumab. The participants will be selected based on the results of a screening HRD gene panel.